MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, approaches to target cellular effectors of BCR-ABL, such as the PI3K/mTOR pathway, may provide alternative strategies to the use of TKIs to overcome resistance in refractory CML.